Patrick C Ma

Summary

Affiliation: Case Western Reserve University
Country: USA

Publications

  1. ncbi request reprint High-throughput mutational analysis of the human cancer genome
    Patrick C Ma
    University Hospitals of Cleveland, Division of Hematology Oncology, Department of Medicine, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
    Pharmacogenomics 7:597-612. 2006
  2. pmc Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity
    Z Tang
    Division of Hematology Oncology, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center and Ireland Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
    Oncogene 28:518-33. 2009
  3. pmc Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
    Z Tang
    Division of Hematology Oncology, Department of Medicine, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
    Br J Cancer 99:911-22. 2008
  4. ncbi request reprint Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
    Ramasamy Jagadeeswaran
    Section of Hematology Oncology, Department of Medicine, University of Chicago Cancer Research Center, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Cancer Res 66:352-61. 2006
  5. ncbi request reprint In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor
    Chunying Wu
    Division of Radiopharmaceutical Science, Case Center for Imaging Research, Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Med Chem 53:139-46. 2010
  6. pmc Ethnic differences and functional analysis of MET mutations in lung cancer
    Soundararajan Krishnaswamy
    Department of Medicine, The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 15:5714-23. 2009
  7. pmc Expression and mutational analysis of MET in human solid cancers
    Patrick C Ma
    Division of Hematology Oncology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Genes Chromosomes Cancer 47:1025-37. 2008
  8. pmc MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
    Weiwen Fan
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer Res 71:4494-505. 2011
  9. ncbi request reprint A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin
    Patrick C Ma
    Section of Hematology Oncology, Department of Medicine, Pritzker School of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 11:2312-9. 2005
  10. ncbi request reprint Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies
    Zhiwei Yu
    Division of Hematology Oncology, Case Western Reserve University, Cleveland, OH 44106 7284, USA
    Cancer Res 67:10417-27. 2007

Research Grants

  1. Studies of Alternations of c-MET in SCLC
    Patrick Ma; Fiscal Year: 2007

Collaborators

Detail Information

Publications35

  1. ncbi request reprint High-throughput mutational analysis of the human cancer genome
    Patrick C Ma
    University Hospitals of Cleveland, Division of Hematology Oncology, Department of Medicine, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
    Pharmacogenomics 7:597-612. 2006
    ..Personalized cancer therapy based on tumor-specific mutations will be a realistic goal in the near future...
  2. pmc Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity
    Z Tang
    Division of Hematology Oncology, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center and Ireland Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
    Oncogene 28:518-33. 2009
    ..Improved efficacy of targeted kinase inhibitors may be achieved by targeting the dominant activating mutations present...
  3. pmc Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
    Z Tang
    Division of Hematology Oncology, Department of Medicine, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
    Br J Cancer 99:911-22. 2008
    ..Furthermore, optimised inhibition may be further achieved with MET inhibition in combination with erlotinib or an irreversible EGFR-TKI...
  4. ncbi request reprint Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
    Ramasamy Jagadeeswaran
    Section of Hematology Oncology, Department of Medicine, University of Chicago Cancer Research Center, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Cancer Res 66:352-61. 2006
    ..Ultimately, c-Met would be an important target for therapy against MPM...
  5. ncbi request reprint In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor
    Chunying Wu
    Division of Radiopharmaceutical Science, Case Center for Imaging Research, Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Med Chem 53:139-46. 2010
    ..These studies demonstrated that [11C]14-PET is an appropriate imaging marker for quantification of MET receptor in vivo, which can facilitate efficacy evaluation in the clinical development of MET-targeted cancer therapeutics...
  6. pmc Ethnic differences and functional analysis of MET mutations in lung cancer
    Soundararajan Krishnaswamy
    Department of Medicine, The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 15:5714-23. 2009
    ....
  7. pmc Expression and mutational analysis of MET in human solid cancers
    Patrick C Ma
    Division of Hematology Oncology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Genes Chromosomes Cancer 47:1025-37. 2008
    ..MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker...
  8. pmc MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
    Weiwen Fan
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer Res 71:4494-505. 2011
    ..Our findings prompt prospective clinical investigations using BH3-mimetics combined with targeted receptor kinase inhibitors to optimize and improve clinical outcomes in lung-cancer treatment...
  9. ncbi request reprint A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin
    Patrick C Ma
    Section of Hematology Oncology, Department of Medicine, Pritzker School of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Clin Cancer Res 11:2312-9. 2005
    ..Here, we characterized a small molecule c-MET inhibitor, PHA665752, and tested its cooperation with the mammalian target of rapamycin inhibitor as potential targeted therapy...
  10. ncbi request reprint Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies
    Zhiwei Yu
    Division of Hematology Oncology, Case Western Reserve University, Cleveland, OH 44106 7284, USA
    Cancer Res 67:10417-27. 2007
    ..These results identify novel mutations mediating resistance to irreversible EGFR inhibitors and reveal alternative strategies to overcome or prevent the development of resistance in EGFR-mutant non-small cell lung cancers...
  11. ncbi request reprint ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors
    Rakesh Bagai
    Case Western Reserve University, Ireland Cancer Center, University Hospitals Case Medical Center, Division of Hematology Oncology, Department of Medicine, 10900 Euclid Avenue, WRB 2 123, Cleveland, OH 44106, USA
    IDrugs 13:404-14. 2010
    ....
  12. ncbi request reprint Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib
    Greg V Manson
    Division of Hematology Oncology, Department of Medicine, Case Western Reserve University, University Hospitals Case Medical Center, Ireland Cancer Center, and Case Comprehensive Cancer Center, Cleveland, OH, USA
    Clin Lung Cancer 11:57-60. 2010
    ..We also present discussion on the evolving paradigm of the use of erlotinib in lung cancer and the current status of determinants of sensitivity in pemetrexed chemotherapy...
  13. pmc Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
    Zhenfeng Zhang
    1 Department of Pathology, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center and Ireland Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, USA
    Nat Genet 44:852-60. 2012
    ..These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer...
  14. ncbi request reprint Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
    Patrick C Ma
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois, USA
    Cancer Res 65:1479-88. 2005
    ..These results indicate that c-Met inhibition will be an important therapeutic strategy against NSCLC to improve its clinical outcome...
  15. ncbi request reprint ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material
    Eugen C Minca
    Departments of Molecular Pathology, Cytopathology, and Anatomic Pathology, Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland, Ohio Departments of Translational Hematology and Oncology Research, and Solid Tumor Oncology, Taussig Cancer Institute, Cleveland, Ohio and Respiratory Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    J Thorac Oncol 9:464-8. 2014
    ..On limited samples such as fine needle aspiration-derived cytoblocks, FISH for ALK is often uninformative. FISH performed on liquid-based ThinPrep slides (ThinPrep-FISH) may represent a robust alternative...
  16. pmc Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer
    Anita Schwandt
    Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA
    J Thorac Oncol 7:751-4. 2012
    ..In conclusion, RA has single-agent activity in relapsed, sensitive SCLC with manageable toxicities but is unlikely to provide any superiority compared to existing agents for this disease...
  17. ncbi request reprint Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies
    Sascha Dietrich
    Section of Hematology Oncology, Department of Medicine, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    J Environ Pathol Toxicol Oncol 24:149-62. 2005
    ..Finally, c-MET, when mutated or overexpressed in malignant cells, serves as an important therapeutic target, and the most recent data with respect to its inhibition are also summarized in this review...
  18. doi request reprint ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH
    Eugen C Minca
    Departments of Molecular and Anatomic Pathology, Pathology and Laboratory Medicine Institute, Cleveland, OH, USA
    J Mol Diagn 15:341-6. 2013
    ..The high concordance with FISH warrants IHC's routine use as the initial component of an algorithmic approach to clinical ALK testing in NSCLC, followed by reflex FISH confirmation of IHC-positive cases...
  19. doi request reprint Personalized targeted therapy in advanced non-small cell lung cancer
    Patrick C Ma
    Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cleve Clin J Med 79:eS56-60. 2012
    ..As our understanding of tumor heterogeneity and tumor resistance mechanisms evolves, more rational therapies and combinations of therapies can be expected...
  20. ncbi request reprint MET signaling: novel targeted inhibition and its clinical development in lung cancer
    Yan Feng
    Department of Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    J Thorac Oncol 7:459-67. 2012
    ....
  21. ncbi request reprint Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer
    Yan Feng
    Department of Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer Discov 1:550-4. 2011
    ..Serum and tissue studies also revealed predictive biomarkers for therapeutic response to MET inhibition...
  22. ncbi request reprint Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
    Gautam Maulik
    Department of Medicine, Division of Adult Oncology, Lowe Center for Thoracic Oncology, Binney Street, Boston, MA 02115, USA
    Cytokine Growth Factor Rev 13:41-59. 2002
    ..Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized...
  23. ncbi request reprint The role of ephrins and Eph receptors in cancer
    Hanna Surawska
    Section of Hematology Oncology, Department of Medicine, The University of Chicago Medical Center, Pritzker School of Medicine, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA
    Cytokine Growth Factor Rev 15:419-33. 2004
    ..This review emphasizes the biology of Eph/ephrin as well as the potential for novel targeted therapy through this pathway...
  24. ncbi request reprint Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer
    Ajit Bharti
    Department of Medicine, Center for Molecular Stress Response, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Anticancer Res 24:1031-8. 2004
    ..Small cell lung cancer (SCLC) frequently presents as metastatic disease. It would be useful to detect serum tumor biomarkers at an earlier stage in order to improve the overall survival...
  25. doi request reprint A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
    Ann M Mauer
    University of Chicago Medical Center, Chicago, Illinois 60637, USA
    J Thorac Oncol 3:631-6. 2008
    ..To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC)...
  26. ncbi request reprint Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer
    Gautam Maulik
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 8:620-7. 2002
    ..These results demonstrate that c-Met/HGF pathway is functional in SCLC, and it would be useful to target this pathway toward novel therapy...
  27. ncbi request reprint Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells
    Takashi Kijima
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:6304-11. 2002
    ..Inhibition of both the CXCR4 and the c-Kit downstream events could be a promising therapeutic approach in SCLC...
  28. ncbi request reprint Circulating tumor cells and serum tumor biomarkers in small cell lung cancer
    Patrick C Ma
    Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Womens s Hospital, Harvard Medical School, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Anticancer Res 23:49-62. 2003
    ..It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication and finally treatment of SCLC with potential novel molecularly-targeted therapeutics...
  29. ncbi request reprint c-Met: structure, functions and potential for therapeutic inhibition
    Patrick C Ma
    Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Metastasis Rev 22:309-25. 2003
    ..Most importantly, current data on c-Met suggest that when mutated or overexpressed in malignant cells, c-Met would serve as an important therapeutic target...
  30. ncbi request reprint Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer
    Nazia F Jafri
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Environ Pathol Toxicol Oncol 22:147-65. 2003
    ..RTKs have also been shown to be important in the metastasis of cancer cells. The roles of RTKs in the mechanism of metastasis are detailed in this review, with special emphasis on downstream signal transduction from RTK signaling...
  31. ncbi request reprint c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions
    Patrick C Ma
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 63:6272-81. 2003
    ..It would now be useful to study the inhibition of c-MET as a therapeutic target against SCLC...
  32. ncbi request reprint Therapeutic targeting of the receptor tyrosine kinase Met
    Martin Sattler
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Cancer Treat Res 119:121-38. 2004
  33. ncbi request reprint Therapeutic targeting of receptor tyrosine kinases in lung cancer
    Nicholas W Choong
    University of Chicago Medical Center, Pritzker School of Medicine, MC 2115, 5841, S Maryland Avenue, Chicago, IL 60615, USA
    Expert Opin Ther Targets 9:533-59. 2005
    ..Through understanding of receptor tyrosine kinases and the utilisation of specific inhibitors, it is hopeful that a dramatic impact will be made on the biology and therapy for lung cancer...
  34. ncbi request reprint Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation
    Nicholas W Choong
    Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Nat Clin Pract Oncol 3:50-7; quiz 1 p following 57. 2006
    ..She failed further chemotherapy treatments and subsequently developed extensive symptomatic leptomeningeal carcinomatosis associated with diplopia, hemiparesis, weight loss, and incontinence...
  35. ncbi request reprint Biomarker discovery in lung cancer--promises and challenges of clinical proteomics
    Ajit Bharti
    Center for Molecular Stress Response Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Mass Spectrom Rev 26:451-66. 2007
    ..It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication, and finally the treatment of lung cancer with potential novel molecularly targeted therapeutics...

Research Grants2

  1. Studies of Alternations of c-MET in SCLC
    Patrick Ma; Fiscal Year: 2007
    ..The role of various inhibitors of c-Met and its mutants in SCLC would be further defined aiming to translate into novel targeted-therapeutics. ..